Binding of STAT5a and STAT5b to a Single Element Resembling a  -Interferon-Activated Sequence Mediates the Growth Hormone Induction of the Mouse Acid-Labile Subunit Promoter in Liver Cells

1998 ◽  
Vol 12 (5) ◽  
pp. 675-687 ◽  
Author(s):  
G. T. Ooi
2000 ◽  
Vol 165 (2) ◽  
pp. 271-279 ◽  
Author(s):  
RC Baxter ◽  
M Svejkar ◽  
MJ Khosravi ◽  
GL Bennett ◽  
KV Hardman ◽  
...  

The acid-labile subunit (ALS) of the high molecular weight insulin-like growth factor binding protein complex is a liver-derived glycoprotein which is regulated by growth hormone and serves as a serum marker of growth hormone action. We have compared the measurement of ALS by four immunoassay methods (two RIAs, two ELISAs) utilizing various polyclonal and monoclonal antibodies raised against natural or recombinant human ALS, or synthetic ALS peptides. Despite the variety of methodologies and reagents, results obtained by the four methods were highly correlated for 125 sera from various patient groups, and when compared for individual groups of sera from healthy children and adults, growth hormone-deficient children and adults, and subjects with acromegaly. Some weaker correlations among methods were seen when measuring ALS levels in groups of sera from pregnant subjects and subjects with chronic renal failure. An assay using antibodies raised against recombinant ALS yielded lower apparent values than the other methods in patient sera, the discrepancy probably being attributable to a difference in standardization. We conclude that a variety of assay formats and reagents can yield serum ALS values of potential clinical utility.


2020 ◽  
pp. 1-9
Author(s):  
Diana-Alexandra Ertl ◽  
Jiajia Chen ◽  
Andreas Gleiss ◽  
Dominik Janu ◽  
Susanne Sagmeister ◽  
...  

<b><i>Background:</i></b> The acid-labile subunit (ALS) is a crucial factor in the tertiary complex. IGF-I and IGFBP-3 are routinely measured during the diagnostic work-up for growth hormone deficiency (GHD). The aim of the study is to evaluate the relevance of serum ALS as an additional biomarker in the diagnosis of GHD. <b><i>Methods:</i></b> Ninety-one children undergoing standard diagnostic work-up for GHD were included in this retrospective study. Inclusion criteria were evidence-based auxological cutoffs, IGF-I and IGFBP-3 &#x3c;−2 SDS at first presentation, at least 1 growth hormone (GH) stimulation test, and IGF-I, IGFBP-3, and ALS measurements on the same day. Statistical analysis was performed by ROC as well as by odds ratio calculations. <b><i>Results:</i></b> Forty-seven of 90 participants presented with peak GH values under the cutoff of 7 ng/mL. AUC from a model containing only IGF-I was 0.76 and 0.68 when using only ALS. A model containing IGF-I, IGFBP-3, and ALS (AUC = 0.77) did not improve the result compared to the combination of IGF-I/IGFBP-3 (0.77) or IGF-I/ALS (0.76). Furthermore, the variation in the outcome (GH peak &#x3c;/≥7) explained by IGF-I only amounts to 20.4%, while that explained by IGFBP-3 and ALS is only 10.6 and 7.8%, respectively. The sensitivity to diagnose GHD at respective concentrations of −2.0 SDS was 48% for IGF-I, 38% for IGFBP-3, and only 8% for ALS. <b><i>Conclusion:</i></b> Determination of serum ALS alone or in combination with IGF-I and IGFBP-3 did not improve definition of biochemical GHD in a cohort of short children and adolescents with suspected growth disorder. However, performance of IGFBP-3 in this context was not statistically superior to ALS.


Endocrinology ◽  
2009 ◽  
Vol 150 (7) ◽  
pp. 3145-3152 ◽  
Author(s):  
Iori Ueki ◽  
Sarah L. Giesy ◽  
Kevin J. Harvatine ◽  
Jin Wook Kim ◽  
Yves R. Boisclair

Endocrinology ◽  
2000 ◽  
Vol 141 (2) ◽  
pp. 833-838 ◽  
Author(s):  
Adisak Suwanichkul ◽  
Yves R. Boisclair ◽  
Robert C. Olney ◽  
Susan K. Durham ◽  
David R. Powell

Sign in / Sign up

Export Citation Format

Share Document